Carole Ben-Maimon

At a glance: Carole Ben-Maimon is CEO, President at Larimar Therapeutics (LRMR). Their latest SEC Form 4, filed Nov 12, 2026, reported a purchase of $50K. On file: 1 purchase line ($50K) and 0 sale lines ($0).

Disclosed holdings: about $1.2M of LRMR stock: 386,326 shares reported on their latest Form 4 (filed Nov 12, 2026), valued at the Nov 13, 2026 close of $3.02. This counts only LRMR shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO, President at Larimar Therapeutics, Inc. (LRMR)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—

Avg. 90-day return—

vs. S&P 500—

Beat the market—

Paper profit on buys+$5K

Total bought / sold$50K / $0

Every purchase since 2022

From the SEC's insider data sets: each open-market buy by Carole Ben-Maimon, matched to how the stock did over the next 90 days against the S&P 500.

2 of 2 buys beat the S&P 500 (100%), median +29.5% vs. the index. Small sample: treat with care. All insider buys: 46%.

Stock	Filed	90 days vs. S&P 500
LRMR	May 18, 2023	+1.1%
LRMR	Sep 20, 2022	+57.9%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed	Stock	Type	Shares	Price	Value	Since
Nov 12SEC	LRMRLarimar Therapeutics, Inc.First buy in 3 yrsPast buys 2/2 beat S&P	Buy	18,050386,326 held (+5%)	$2.77	$50K	+9.1%

Buy
CEO, President Carole Ben-maimon bought $50K of LRMR at $2.77 — first open-market purchase in our records.
Nov 12, 2026

Follow Carole Ben-Maimon

Get one email when Carole Ben-Maimon files a new purchase or sale. Free.

At most one email a day about Carole Ben-Maimon, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.